At a glance
ClinicalIndex Comparison RecordN/ACompleted· 18 enrolled
Drug / intervention
Retin-A and microdermabrasion +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of the RevLite Q-Switched Nd:YAG Laser System With Smart Infinite (SI) Handpiece for the Treatment of Refractory Mixed Type Melasma
In Brief
A clinical study evaluating Q-Switched Nd:YAG Laser (RevLite) and Retin-A and microdermabrasion for Refractory Mixed Type Melasma. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the RevLite laser in the treatment of refractory mixed type melasma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Mixed Type Melasma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedApr 2011
Primary CompletionMar 2012
TodayJul 2026
First PostedApr 14, 2011
Enrollment StartApr 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.2 years ago
Interventions
Q-Switched Nd:YAG Laser (RevLite)device
Laser treatment added to a microdermabrasion and topical lightening agent regimen
Retin-A and microdermabrasiondrug
Microdermabrasion and topical lightening agent regimen